Bengamidderivater, fremgangsmater for fremstilling og anvendelse av dette for behandling av cancer

Det beskrives bengamidderivater som produseres av mikroorganismen Myxococcus virescens ST2005\611 (DSM 15898) under farmentering. Det beskrives videre anvendelsen av derivatene for behandling av cancer, medikamenter inneholdende derivatene og videre en fremgangsmåte for fremstilling av bengamidene med formel IV. Videre beskrives mikroorganismen Myxococcus virescens ST2005\611 (DSM 15898). Preparation of bengamide compounds (3-alkenoylamino-hexahydroazepin-2-one derivatives) (A) involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants). Some of the bengamide derivatives (A) (i.e. 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino-hexahydroazepin-2-ones) are new. Preparation of bengamide compounds of formula (A) or their salts involves fermenting Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants) in a culture medium, isolating the obtained (A) from the culture medium and optionally derivatizing and/or salifying the product. [Image] R 1H or 1-6C alkyl; R 2H or OH; R 3H or 2-7C alkanoyl; R 4Me or Et. Independent claims are included for: (1) bengamide derivatives of formula (B) (this is structure (A) where R 4 = Et) and their salts as new compounds; (2) the new microorganism Myxococcus virescens ST200611 (DSM 15898); and (3) the use of Myxococcus virescens ST200611 (DSM 15898) (or its variants and/or mutants) for the production of (A). ACTIVITY : Cytostatic. A specific diastereomer of 3-(2-methoxy-8-methyl-3,4,5-trihydroxydec-6E-enoylamino)-hexahydroazepin-2-one (A1) had TC 5 0 values of 6 mu M and 10 mu M for inhibition of proliferation of Hep-G2 and Colo 205 cells respectively. MECHANISM OF ACTION : Mitosis inhibitor; Cell cycle regulator.